NASDAQ:BLPH Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis $0.06 +0.02 (+57.14%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSustainabilityTrends About Bellerophon Therapeutics Stock (NASDAQ:BLPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BLPH alerts:Sign Up Key Stats Today's Range$0.04▼$0.0650-Day Range$0.04▼$0.0652-Week Range$0.03▼$0.10Volume276 shsAverage Volume31,595 shsMarket Capitalization$672,650.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Read More… Central Bank Abandons USD (Ad)You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! Get Your FREE Gold Investor Kit NOW! Bellerophon Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks9th Percentile Overall ScoreBLPH MarketRank™: Bellerophon Therapeutics scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bellerophon Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bellerophon Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bellerophon Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBellerophon Therapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BLPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBellerophon Therapeutics does not currently pay a dividend.Dividend GrowthBellerophon Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.86 Short InterestThere is no current short interest data available for BLPH. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Bellerophon Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for BLPH on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bellerophon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Bellerophon Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 10.61% of the stock of Bellerophon Therapeutics is held by institutions.Read more about Bellerophon Therapeutics' insider trading history. Receive BLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BLPH Stock News HeadlinesBellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.comNovember 18, 2024 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated by Analysts at StockNews.comNovember 12, 2024 | americanbankingnews.comCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! November 22, 2024 | Desko Digital (Ad)Adocia SA (A89.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comBellerophon Therapeutics, Inc. (BLPH)February 25, 2024 | uk.finance.yahoo.comBellerophon Therapeutics Inc (BLPH)February 15, 2024 | investing.comBellerophon Offers Series A Stock in Private SaleJanuary 31, 2024 | msn.comHilco Streambank Seeks Offers to Acquire Patent Portfolio and Material Inventory of Biotherapeutics Company BellerophonNovember 28, 2023 | benzinga.comSee More Headlines BLPH Stock Analysis - Frequently Asked Questions How have BLPH shares performed this year? Bellerophon Therapeutics' stock was trading at $0.0370 at the beginning of the year. Since then, BLPH shares have increased by 48.6% and is now trading at $0.0550. View the best growth stocks for 2024 here. How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter. When did Bellerophon Therapeutics' stock split? Bellerophon Therapeutics shares reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Bellerophon Therapeutics IPO? Bellerophon Therapeutics (BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. How do I buy shares of Bellerophon Therapeutics? Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), iBio (IBIO) and Meta Platforms (META). Company Calendar Last Earnings8/14/2023Today11/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLPH CUSIPN/A CIK1600132 Webwww.bellerophon.com Phone(908) 574-4770FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book0.20Miscellaneous Outstanding Shares12,230,000Free Float11,597,000Market Cap$672,650.00 OptionableNo Data Beta0.71 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:BLPH) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredAmerica’s Pro-Crypto AgendaCash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Crypto 101 Media | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellerophon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.